OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE
Identifieur interne : 000499 ( Main/Exploration ); précédent : 000498; suivant : 000500OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE
Auteurs : R. Furie [États-Unis] ; M. Scheinberg [Brésil] ; G. Leon [Pérou] ; E. B. Ramiterre [Philippines] ; M. Thomas [Inde] ; A. D. Chu ; C. Hislop ; R. S. Martin ; M. A. Petri [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Background Blisibimod, a potent inhibitor of B cell activating factor (BAFF), was evaluated in a Phase 2b clinical trial in patients with SLE. Objectives To determine the effect of subcutaneous blisibimod on SLE disease activity, including rate of response to the SLE responder index (SRI). Methods 547 serologically-active SLE patients with baseline SELENA-SLEDAI ≥6 were randomized to receive blisibimod (100mg weekly (QW), 200mg QW, or 200mg Q4W) or placebo in matchin dosing regimens. The primary endpoint was a comparison at Week 24 of the percentage of subjects in the pooled blisibimod and placebo groups who achieved an SRI-5 response (SRI with ≥5 point improvement in SELENA–SLEDAI). Results The primary endpoint was not met due to the lack of efficacy in the two lower doses. However, SRI-5 response was higher in subjects receiving blisibimod 200mg QW compared with placebo (p=0.02 at Week 20). SRI improvements compared with placebo were higher still in subjects who attained SELENA–SLEDAI improvements of ≥8, and in patients with severe disease (SELENA–SLEDAI≥10 and receiving corticosteroids, n=278, figure 1 ). Despite declining patient numbers, response to blisibimod remained higher than placebo beyond Week 24 while N>30 subjects per cohort. Numerically higher response was also observed with blisibimod in all components of the SRI. Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections compared with placebo. Image/graphConclusions These are the first evidence that SLE disease activity may be improved with subcutaneous injections of a novel biologic therapy. Disclosure of Interest R. Furie Consultant for: Anthera Pharmaceuticals, M. Scheinberg: None Declared, G. Leon: None Declared, E. Ramiterre: None Declared, M. Thomas: None Declared, A. Chu: None Declared, C. Hislop Employee of: Anthera Pharmaceuticals, R. Martin: None Declared, M. Petri Employee of: Anthera Pharmaceuticals
Url:
DOI: 10.1136/annrheumdis-2013-eular.321
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F38
- to stream Istex, to step Curation: 000F38
- to stream Istex, to step Checkpoint: 000017
- to stream Main, to step Merge: 000498
- to stream Main, to step Curation: 000499
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE</title><author><name sortKey="Furie, R" sort="Furie, R" uniqKey="Furie R" first="R." last="Furie">R. Furie</name></author><author><name sortKey="Scheinberg, M" sort="Scheinberg, M" uniqKey="Scheinberg M" first="M." last="Scheinberg">M. Scheinberg</name></author><author><name sortKey="Leon, G" sort="Leon, G" uniqKey="Leon G" first="G." last="Leon">G. Leon</name></author><author><name sortKey="Ramiterre, E B" sort="Ramiterre, E B" uniqKey="Ramiterre E" first="E. B." last="Ramiterre">E. B. Ramiterre</name></author><author><name sortKey="Thomas, M" sort="Thomas, M" uniqKey="Thomas M" first="M." last="Thomas">M. Thomas</name></author><author><name sortKey="Chu, A D" sort="Chu, A D" uniqKey="Chu A" first="A. D." last="Chu">A. D. Chu</name></author><author><name sortKey="Hislop, C" sort="Hislop, C" uniqKey="Hislop C" first="C." last="Hislop">C. Hislop</name></author><author><name sortKey="Martin, R S" sort="Martin, R S" uniqKey="Martin R" first="R. S." last="Martin">R. S. Martin</name></author><author><name sortKey="Petri, M A" sort="Petri, M A" uniqKey="Petri M" first="M. A." last="Petri">M. A. Petri</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F84B96C3EE876A6D7F43D3F2DFF816080FD163F5</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.321</idno><idno type="url">https://api.istex.fr/document/F84B96C3EE876A6D7F43D3F2DFF816080FD163F5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F38</idno><idno type="wicri:Area/Istex/Curation">000F38</idno><idno type="wicri:Area/Istex/Checkpoint">000017</idno><idno type="wicri:doubleKey">0003-4967:2013:Furie R:op:effects:of</idno><idno type="wicri:Area/Main/Merge">000498</idno><idno type="wicri:Area/Main/Curation">000499</idno><idno type="wicri:Area/Main/Exploration">000499</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE</title><author><name sortKey="Furie, R" sort="Furie, R" uniqKey="Furie R" first="R." last="Furie">R. Furie</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>North Shore–Long Island Jewish Health System, Lake Success New York</wicri:regionArea><wicri:noRegion>Lake Success New York</wicri:noRegion></affiliation></author><author><name sortKey="Scheinberg, M" sort="Scheinberg, M" uniqKey="Scheinberg M" first="M." last="Scheinberg">M. Scheinberg</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Leon, G" sort="Leon, G" uniqKey="Leon G" first="G." last="Leon">G. Leon</name><affiliation wicri:level="1"><country xml:lang="fr">Pérou</country><wicri:regionArea>Rheumatology Gynecology & Reproduction Institute, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="Ramiterre, E B" sort="Ramiterre, E B" uniqKey="Ramiterre E" first="E. B." last="Ramiterre">E. B. Ramiterre</name><affiliation wicri:level="1"><country xml:lang="fr">Philippines</country><wicri:regionArea>Brokenshire Memorial Hospital, Davao City</wicri:regionArea><wicri:noRegion>Davao City</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, M" sort="Thomas, M" uniqKey="Thomas M" first="M." last="Thomas">M. Thomas</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Health and Research Centre, Trivandrum, Kerala</wicri:regionArea><wicri:noRegion>Kerala</wicri:noRegion></affiliation></author><author><name sortKey="Chu, A D" sort="Chu, A D" uniqKey="Chu A" first="A. D." last="Chu">A. D. Chu</name><affiliation><wicri:noCountry code="no comma">Anthera Pharmaceuticals</wicri:noCountry></affiliation></author><author><name sortKey="Hislop, C" sort="Hislop, C" uniqKey="Hislop C" first="C." last="Hislop">C. Hislop</name><affiliation><wicri:noCountry code="subField">Hayward</wicri:noCountry></affiliation></author><author><name sortKey="Martin, R S" sort="Martin, R S" uniqKey="Martin R" first="R. S." last="Martin">R. S. Martin</name><affiliation><wicri:noCountry code="subField">Hayward</wicri:noCountry></affiliation></author><author><name sortKey="Petri, M A" sort="Petri, M A" uniqKey="Petri M" first="M. A." last="Petri">M. A. Petri</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore</wicri:regionArea><placeName><settlement type="city">Baltimore</settlement><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A90">A90</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">F84B96C3EE876A6D7F43D3F2DFF816080FD163F5</idno><idno type="DOI">10.1136/annrheumdis-2013-eular.321</idno><idno type="href">annrheumdis-72-A90-3.pdf</idno><idno type="ArticleID">annrheumdis-2013-eular.321</idno><idno type="local">annrheumdis;72/Suppl_3/A90-c</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Blisibimod, a potent inhibitor of B cell activating factor (BAFF), was evaluated in a Phase 2b clinical trial in patients with SLE. Objectives To determine the effect of subcutaneous blisibimod on SLE disease activity, including rate of response to the SLE responder index (SRI). Methods 547 serologically-active SLE patients with baseline SELENA-SLEDAI ≥6 were randomized to receive blisibimod (100mg weekly (QW), 200mg QW, or 200mg Q4W) or placebo in matchin dosing regimens. The primary endpoint was a comparison at Week 24 of the percentage of subjects in the pooled blisibimod and placebo groups who achieved an SRI-5 response (SRI with ≥5 point improvement in SELENA–SLEDAI). Results The primary endpoint was not met due to the lack of efficacy in the two lower doses. However, SRI-5 response was higher in subjects receiving blisibimod 200mg QW compared with placebo (p=0.02 at Week 20). SRI improvements compared with placebo were higher still in subjects who attained SELENA–SLEDAI improvements of ≥8, and in patients with severe disease (SELENA–SLEDAI≥10 and receiving corticosteroids, n=278, figure 1 ). Despite declining patient numbers, response to blisibimod remained higher than placebo beyond Week 24 while N>30 subjects per cohort. Numerically higher response was also observed with blisibimod in all components of the SRI. Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections compared with placebo. Image/graphConclusions These are the first evidence that SLE disease activity may be improved with subcutaneous injections of a novel biologic therapy. Disclosure of Interest R. Furie Consultant for: Anthera Pharmaceuticals, M. Scheinberg: None Declared, G. Leon: None Declared, E. Ramiterre: None Declared, M. Thomas: None Declared, A. Chu: None Declared, C. Hislop Employee of: Anthera Pharmaceuticals, R. Martin: None Declared, M. Petri Employee of: Anthera Pharmaceuticals</div></front></TEI><affiliations><list><country><li>Brésil</li><li>Inde</li><li>Philippines</li><li>Pérou</li><li>États-Unis</li></country><region><li>Maryland</li><li>État de São Paulo</li></region><settlement><li>Baltimore</li><li>São Paulo</li></settlement></list><tree><noCountry><name sortKey="Chu, A D" sort="Chu, A D" uniqKey="Chu A" first="A. D." last="Chu">A. D. Chu</name><name sortKey="Hislop, C" sort="Hislop, C" uniqKey="Hislop C" first="C." last="Hislop">C. Hislop</name><name sortKey="Martin, R S" sort="Martin, R S" uniqKey="Martin R" first="R. S." last="Martin">R. S. Martin</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Furie, R" sort="Furie, R" uniqKey="Furie R" first="R." last="Furie">R. Furie</name></noRegion><name sortKey="Petri, M A" sort="Petri, M A" uniqKey="Petri M" first="M. A." last="Petri">M. A. Petri</name></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Scheinberg, M" sort="Scheinberg, M" uniqKey="Scheinberg M" first="M." last="Scheinberg">M. Scheinberg</name></region></country><country name="Pérou"><noRegion><name sortKey="Leon, G" sort="Leon, G" uniqKey="Leon G" first="G." last="Leon">G. Leon</name></noRegion></country><country name="Philippines"><noRegion><name sortKey="Ramiterre, E B" sort="Ramiterre, E B" uniqKey="Ramiterre E" first="E. B." last="Ramiterre">E. B. Ramiterre</name></noRegion></country><country name="Inde"><noRegion><name sortKey="Thomas, M" sort="Thomas, M" uniqKey="Thomas M" first="M." last="Thomas">M. Thomas</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000499 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000499 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F84B96C3EE876A6D7F43D3F2DFF816080FD163F5
|texte= OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE
}}
| This area was generated with Dilib version V0.6.25. |  |